Skip to main content
SpringerLink
Log in

CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Variability of response to clopidogrel and prasugrel is a multifactorial process, with clinical consequences, and drug-drug interactions have been proposed as potential factors. Biological modulation of clopidogrel response has been demonstrated for atorvastatin and omeprazole. However, investigations assessing clinical relevance of these findings have been heterogeneous, and real clinical impact is still debatable. For new P2Y12 blockers, such as prasugrel, with less variability of platelet inhibition, these interactions are not significant; accordingly, no dose adjustment is required. The present review aims to summarize available scientific evidence about CYP-mediated pharmacologic interference with optimal platelet inhibition in patients treated with thienopyridine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertrand, M. E., Rupprecht, H. J., Urban, P., Gershlick, A. H., & Investigators, F. T. (2000). Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation, 102, 624–629.

    Article  PubMed  CAS  Google Scholar 

  2. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., & Fox, K. K. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine, 345, 494–502.

    Article  PubMed  CAS  Google Scholar 

  3. Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., et al. (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet, 358, 527–533.

    Article  CAS  Google Scholar 

  4. Fuster, V., Stein, B., Ambrose, J. A., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1990). Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation, 82(Suppl 3), 1147–1159.

    Google Scholar 

  5. Storey, R. F., Newby, L. J., & Heptinstall, S. (2001). Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets, 12, 443–447.

    Article  PubMed  CAS  Google Scholar 

  6. Dorsam, R. T., & Kunapuli, S. P. (2004). Central role of the P2Y12 receptor in platelet activation. Journal of Clinical Investigation, 113, 340–345.

    PubMed  CAS  Google Scholar 

  7. Savi, P., & Herbert, J. M. (2005). Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis, 31, 174–183.

    Article  PubMed  CAS  Google Scholar 

  8. Steinhubl, S. R., Berger, P. B., Tift Mann, J., III, Fry, E. T., DeLago, A., Wilmer, C., et al. (2002). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. Journal of the American Medical Association, 288, 2411–2420.

    Article  PubMed  CAS  Google Scholar 

  9. Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., et al. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine, 352, 1179–1189.

    Article  PubMed  CAS  Google Scholar 

  10. Chen, Z. M., Jiang, L. X., Chen, Y. P., Xie, J. X., Pan, H. C., Peto, R., et al. (2005). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 366, 1607–1621.

    Article  PubMed  CAS  Google Scholar 

  11. The ACTIVE Investigators, Connolly, S. J., Pogue, J., Hart, R. G., Hohnloser, S. H., Pfeffer, M., et al. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England Journal of Medicine, 360, 2066–2078.

    Article  PubMed  Google Scholar 

  12. Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Blomstrom-Lundqvist, C., Crea, F., et al. (2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. European Heart Journal, 29, 2909–2945.

    Article  PubMed  Google Scholar 

  13. Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., et al. (2010). Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 31(20), 2501–2555.

    Article  PubMed  Google Scholar 

  14. Diener, H. C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., et al. (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364, 331–337.

    Article  PubMed  CAS  Google Scholar 

  15. Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., et al. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine, 354, 1706–1717.

    Article  PubMed  CAS  Google Scholar 

  16. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T. A., et al. (2007). Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. Journal of the American College of Cardiology, 49, 1505–1516.

    Article  PubMed  CAS  Google Scholar 

  17. Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I., et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109, 3171–3175.

    Article  PubMed  CAS  Google Scholar 

  18. Cuisset, T., Frere, C., Quilici, J., Barbou, F., Morange, P. E., Hovasse, T., et al. (2006). High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 4, 542–549.

    Article  PubMed  CAS  Google Scholar 

  19. Geisler, T., Langer, H., Wydymus, M., Göhring, K., Zürn, C., Bigalke, B., et al. (2006). Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 27, 2420–2425.

    Article  PubMed  CAS  Google Scholar 

  20. Hochholzer, W., Trenk, D., Bestehorn, H. P., Fischer, B., Valina, C. M., Ferenc, M., et al. (2006). Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742–1750.

    Article  PubMed  CAS  Google Scholar 

  21. Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., et al. (2007). Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. Journal of the American College of Cardiology, 49, 2312–2317.

    Article  PubMed  CAS  Google Scholar 

  22. Cuisset, T., Cayla, G., Frere, C., Quilici, J., Poyet, R., Gaborit, B., et al. (2009). Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Euro Intervention, 5, 325–329.

    PubMed  Google Scholar 

  23. Sibbing, D., Schulz, S., Braun, S., Morath, T., Stegherr, J., Mehilli, J., et al. (2010). Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis, 8, 250–256.

    Article  PubMed  CAS  Google Scholar 

  24. Frere, C., Cuisset, T., Quilici, J., Camoin, L., Carvajal, J., Morange, P. E., et al. (2007). ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 98, 838–843.

    PubMed  CAS  Google Scholar 

  25. Cuisset, T., Hamilos, M., Sarma, J., Sarno, G., Wyffels, E., Vanderheyden, M., et al. (2008). Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. The American Journal of Cardiology, 101, 1700–1703.

    Article  PubMed  CAS  Google Scholar 

  26. Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., et al. (2008). Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. European Heart Journal, 29, 992–1000.

    Article  PubMed  Google Scholar 

  27. Marcucci, R., Gori, A. M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., et al. (2009). Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation, 119, 237–242.

    Article  PubMed  Google Scholar 

  28. Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J., Bal, E. T., et al. (2010). Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 303, 754–762.

    Article  PubMed  CAS  Google Scholar 

  29. Bonello, L., Camoin-Jau, L., Arques, S., et al. (2008). Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Journal of the American College of Cardiology, 51, 1404–1411.

    Article  PubMed  CAS  Google Scholar 

  30. Cuisset, T., Frere, C., Quilici, J., et al. (2008). Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non-responders: a prospective, randomized study. JACC Cardiovascular Interventions, 1, 649–653.

    Article  PubMed  Google Scholar 

  31. Valgimigli, M., Campo, G., de Cesare, N., et al. (2009). Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation, 119, 3215–3222.

    Article  PubMed  CAS  Google Scholar 

  32. Price, M. J., Berger, P. B., Teirstein, P. S., et al. (2011). Standard vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 305, 1097–1105.

    Article  PubMed  CAS  Google Scholar 

  33. Trenk, D., Stone, G. W., Gawaz, M., et al. (2012). A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Journal of the American College of Cardiology, 59(24), 2159–2164.

    Article  PubMed  CAS  Google Scholar 

  34. Collet, J. P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., et al. (2012). bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine, 367, 2100–2109.

    Article  PubMed  CAS  Google Scholar 

  35. Shuldiner, A. R., O’Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302, 849–857.

    Article  PubMed  CAS  Google Scholar 

  36. Lins, R., Broekhuysen, J., Necciari, J., & Deroubaix, X. (1999). Pharmacokinetic profile of 14C-labeled clopidogrel. Seminars in Thrombosis and Hemostasis, 25(Suppl. 2), 29–33.

    PubMed  CAS  Google Scholar 

  37. Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., et al. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis, 84, 891–896.

    PubMed  CAS  Google Scholar 

  38. Kurihara, A., Hagihara, K., Kazui, M., Ishizuka, T., Farid, N. A., & Ikeda, T. (2005). In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in active metabolite formation. Drug Metabolism Reviews, 37(Suppl. 2), 99.

    Google Scholar 

  39. Badyal, D. K., & Dadhich, A. P. (2001). Cytochrome P450 and drug interactions. Indian Journal of Pharmacology, 33, 248–259.

    CAS  Google Scholar 

  40. Lau, W. C., Waskell, L. A., Watkins, P. B., et al. (2003). Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation, 107, 32–37.

    Article  PubMed  CAS  Google Scholar 

  41. Gilard, M., Arnaud, B., Le Gal, G., Abgrall, J. F., & Boschat, J. (2006). Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. Journal of Thrombosis and Haemostasis, 4, 2508–2509.

    Article  PubMed  CAS  Google Scholar 

  42. Neubauer, H., Gunesdogan, B., Hanefeld, C., Spiecker, M., & Mugge, A. (2003). Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study. European Heart Journal, 24, 1744–1749.

    Article  PubMed  CAS  Google Scholar 

  43. Park, Y., Jeong, Y. H., Tantry, U. S., Ahn, J. H., Kwon, T. J., Park, J. R., et al. (2012). Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. European Heart Journal, 33(17), 2151–2162.

    Article  PubMed  CAS  Google Scholar 

  44. Cannon, C. P., Braunwald, E., McCabe, C. H., et al. (2004). PROVE-IT-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine, 350, 1495–1504.

    Article  PubMed  CAS  Google Scholar 

  45. Wienbergen, H. A., Gitt, A. K., Schiele, R., et al. (2003). Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. The American Journal of Cardiology, 92, 285–288.

    Article  PubMed  CAS  Google Scholar 

  46. Wahab, N. N., Cox, J. L., & the ICON Investigators. (2003). Does the use of atorvastatin with clopidogrel increase clinical adverse events after percutaneous coronary intervention? Canadian Journal of Cardiology, 19(Suppl A), 231A–232A.

    Google Scholar 

  47. Brophy, J. M., Babapulle, M. N., Costa, V., & Rinfret, S. (2006). A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 152, 263–269.

    Article  PubMed  CAS  Google Scholar 

  48. Saw, J., Steinhubl, S. R., Berger, P. B., et al. (2003). Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation, 108, 921–924.

    Article  PubMed  CAS  Google Scholar 

  49. Saw, J., Brennan, D. M., Steinhubl, S. R., et al. (2007). Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. Journal of the American College of Cardiology, 50, 291–295.

    Article  PubMed  CAS  Google Scholar 

  50. Lotfi, A., Schweiger, M. J., Giugliano, G. R., Murphy, S. A., & Cannon, C. P. (2008). High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients: A Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. American Heart Journal, 155, 954–958.

    Article  PubMed  CAS  Google Scholar 

  51. Gilard, M., Arnaud, B., Cornily, J. C., et al. (2008). Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. Journal of the American College of Cardiology, 51, 256–260.

    Article  PubMed  CAS  Google Scholar 

  52. Cuisset, T., Frere, C., Quilici, J., et al. (2009). Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. Journal of the American College of Cardiology, 54, 1149–1153.

    Article  PubMed  CAS  Google Scholar 

  53. Sibbing, D., Morath, T., Stegherr, J., et al. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101, 714–719.

    PubMed  CAS  Google Scholar 

  54. Neubauer, H., Engelhardt, A., Kruger, J. C., et al. (2010). Pantoprazole does not influence the antiplatelet effect of clopidogrel: a whole blood aggregometry study after coronary stenting. Journal of Cardiovascular Pharmacology, 56, 91–97.

    Article  PubMed  CAS  Google Scholar 

  55. Siller-Matula, J. M., Spiel, A. O., Lang, I. M., Kreiner, G., Christ, G., & Jilma, B. (2009). Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. American Heart Journal, 157, 148. e1–5.

    Article  PubMed  Google Scholar 

  56. Angiolillo, D. J., Gibson, C. M., Cheng, S., et al. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo controlled, crossover comparison studies. Clinical Pharmacology and Therapeutics, 89, 65–74.

    Article  PubMed  CAS  Google Scholar 

  57. Gaglia, M. A., Torguson, R., Hanna, N., et al. (2010). Relation of proton pump inhibitor use after percutaneous coronary intervention with drug eluting stents to outcomes. The American Journal of Cardiology, 105, 833–838.

    Article  PubMed  CAS  Google Scholar 

  58. Gupta, E., Bansal, D., Sotos, J., & Olden, K. (2010). Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Digestive Diseases and Sciences, 55, 1964–1968.

    Article  PubMed  CAS  Google Scholar 

  59. Evanchan, J., Donnally, M. R., Binkley, P., & Mazzaferri, E. (2010). Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clinical Cardiology, 33, 168–171.

    Article  PubMed  Google Scholar 

  60. Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., et al. (2011). Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 123(5), 474–482.

    Article  PubMed  CAS  Google Scholar 

  61. Ho, P. M., Maddox, T. M., Wang, L., et al. (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 301, 937–944.

    Article  PubMed  CAS  Google Scholar 

  62. Juurlink, D. N., Gomes, T., Ko, D. T., et al. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 180, 713–718.

    Article  PubMed  Google Scholar 

  63. Rassen, J. A., Choudhry, N. K., Avorn, J., & Schneeweiss, S. (2009). Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation, 120, 2322–2329.

    Article  PubMed  CAS  Google Scholar 

  64. Ray, W. A., Murray, K. T., Griffin, M. R., et al. (2010). Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. Annals of Internal Medicine, 152, 337–345.

    Article  PubMed  Google Scholar 

  65. Hulot, J. S., Collet, J. P., Silvain, J., et al. (2010). Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19* loss-of-function allele or proton pump inhibitor coadministration. Journal of the American College of Cardiology, 56, 134–143.

    Article  PubMed  CAS  Google Scholar 

  66. Dunn, S. P., Macaulay, T. E., Brennan, D. M., et al. (2008). Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation, 118(Suppl 2), S81568.

    Google Scholar 

  67. O’Donoghue, M. L., Braunwald, E., Antman, E. M., et al. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet, 374, 989–997.

    Article  PubMed  Google Scholar 

  68. Bhatt, D. L., Cryer, B. L., Contant, C. F., et al. (2010). Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine, 363, 1909–1917.

    Article  PubMed  CAS  Google Scholar 

  69. Wiviott, S. D., Antman, E. M., Winters, K. J., et al. (2005). Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 111(25), 3366–3373.

    Article  PubMed  CAS  Google Scholar 

  70. Brandt, J. T., Payne, C. D., Wiviott, S. D., et al. (2007). A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. American Heart Journal, 153, 9–16.

    Article  Google Scholar 

  71. Wiviott, S. D., Braunwald, E., McCabe, C. H., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001–2015.

    Article  PubMed  CAS  Google Scholar 

  72. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., et al. (2009). Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 119, 2553–2560.

    Article  PubMed  CAS  Google Scholar 

  73. Brandt, J. T., Close, S. L., Iturria, S. J., Payne, C. D., Farid, N. A., Ernest, C. S., II, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis, 5, 2429–2436.

    Article  PubMed  CAS  Google Scholar 

  74. Cuisset, T., Loosveld, M., Morange, P. E., Quilici, J., Moro, P. J., Saut, N., et al. (2012). CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. Journal of the American College of Cardiology Cardiovascular Interventions, 5(12), 1280–7.

    Google Scholar 

  75. O’Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., et al. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 374(9694), 989–997.

    Article  PubMed  Google Scholar 

  76. Aradi, D., Kuliczkowski, W., Atar, D., & Serebruany, V. L. (2012). Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and Haemostasis, 107(2), 338–345.

    Article  PubMed  CAS  Google Scholar 

  77. Farid, N. A., Small, D. S., Payne, C. D., Jakubowski, J. A., Brandt, J. T., Li, Y. G., et al. (2008). Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy, 28(12), 1483–1494.

    Article  PubMed  CAS  Google Scholar 

  78. Pankert, M., Quilici, J., & Cuisset, T. (2012). Role of antiplatelet therapy in secondary prevention of acute coronary syndrome. Journal of Cardiovascular Translational Research, 5(1), 41–51.

    Article  PubMed  Google Scholar 

  79. Siller-Matula, J. M., Lang, I., Christ, G., & Jilma, B. (2008). Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. Journal of the American College of Cardiology, 52(19), 1557–1563.

    Article  PubMed  CAS  Google Scholar 

  80. Sibbing, D., von Beckerath, N., Morath, T., Stegherr, J., Mehilli, J., Sarafoff, N., et al. (2010). Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. European Heart Journal, 31(10), 1205–1211.

    Article  PubMed  CAS  Google Scholar 

  81. Olesen, J. B., Gislason, G. H., Charlot, M. G., Fosbøl, E. L., Andersson, C., Weeke, P., et al. (2011). Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. Journal of the American College of Cardiology, 57(4), 409–417.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Thomas Cuisset has received consultant fees from Daiichi Sankyo and Eli Lilly, research grants from Daiichi Sankyo and Eli Lilly, and lecture fees from AstraZeneca, Daiichi Sankyo, and Eli Lilly. Jacques Quilici has no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Département de Cardiologie, CHU Timone, Marseille, F-13385, France

    Thomas Cuisset & Jacques Quilici

  2. INSERM, UMR1062, F-13385, Marseille, France

    Thomas Cuisset & Jacques Quilici

  3. Faculté de Médecine, Aix-Marseille Université, F-13385, Marseille, France

    Thomas Cuisset & Jacques Quilici

Authors
  1. Thomas Cuisset
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Quilici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Cuisset.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cuisset, T., Quilici, J. CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. J. of Cardiovasc. Trans. Res. 6, 404–410 (2013). https://doi.org/10.1007/s12265-012-9442-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-012-9442-z

Keywords

Search

Navigation